<< Back To Search

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT04973605
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and potentially lead to better management of the disease. Here are some key details about the study:
  • Combination Therapy: The study investigates the effects of combining different treatment methods, which may enhance the effectiveness of the therapy.
  • Targeted Approach: The treatment is designed to target specific characteristics of the disease, which could lead to more personalized care for patients.
  • Patient-Centric Design: The study emphasizes the importance of patient involvement and feedback, ensuring that the treatment aligns with their needs and preferences.
  • Innovative Techniques: Researchers are utilizing advanced techniques to monitor the treatment's impact, which may provide valuable insights into how the disease responds to therapy.
  • Focus on Quality of Life: The study aims not only to improve survival rates but also to enhance the overall quality of life for patients undergoing treatment.
This study is unique because it combines various treatment strategies and focuses on tailoring the approach to individual patient needs. By doing so, it hopes to provide a more effective and supportive treatment experience for those affected by this condition.
Third Opinion AI Generated Synopsis

Trial Summary
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: